Immunome Statistics

Total Valuation

Immunome has a market cap or net worth of $627.70 million. The enterprise value is $469.57 million.

Market Cap	627.70M
Enterprise Value	469.57M

Important Dates

The next estimated earnings date is Tuesday, May 7, 2024, before market open.

Earnings Date	May 7, 2024
Ex-Dividend Date	n/a

Share Statistics

Immunome has 42.73 million shares outstanding. The number of shares has increased by 63.64% in one year.

Shares Outstanding	42.73M
Shares Change (YoY)	+63.64%
Shares Change (QoQ)	+62.62%
Owned by Insiders (%)	18.03%
Owned by Institutions (%)	39.83%
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	43.36
Forward PS	80.35
PB Ratio	5.07
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	33.50
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.63, with zero debt.

Current Ratio	6.63
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -286.40% and return on invested capital (ROIC) is -91.36%.

Return on Equity (ROE)	-286.40%
Return on Assets (ROA)	-129.00%
Return on Capital (ROIC)	-91.36%
Revenue Per Employee	$254,873
Profits Per Employee	-$1.94M
Employee Count	55
Asset Turnover	0.17
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +180.08% in the last 52 weeks. The beta is 1.66, so Immunome's price volatility has been higher than the market average.

Beta (1Y)	1.66
52-Week Price Change	+180.08%
50-Day Moving Average	21.55
200-Day Moving Average	12.72
Relative Strength Index (RSI)	23.97
Average Volume (30 Days)	827,318

Short Selling Information

The latest short interest is 3.75 million, so 8.77% of the outstanding shares have been sold short.

Short Interest	3.75M
Short Previous Month	3.24M
Short % of Shares Out	8.77%
Short % of Float	n/a
Short Ratio (days to cover)	6.26

Income Statement

In the last 12 months, Immunome had revenue of $14.02 million and -$106.81 million in losses. Loss per share was -$5.38.

Revenue	14.02M
Gross Profit	14.02M
Operating Income	-109.53M
Pretax Income	-106.81M
Net Income	-106.81M
EBITDA	-106.08M
EBIT	-106.81M
Loss Per Share	-$5.38

Full Income Statement

Balance Sheet

The company has $138.24 million in cash and no debt, giving a net cash position of $138.24 million or $3.24 per share.

Cash & Cash Equivalents	138.24M
Total Debt	n/a
Net Cash	138.24M
Net Cash Per Share	$3.24
Equity / Book Value	119.88M
Book Value Per Share	2.81
Working Capital	122.87M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$7.57 million and capital expenditures -$831,000, giving a free cash flow of -$8.40 million.

Operating Cash Flow	-7.57M
Capital Expenditures	-831,000
Free Cash Flow	-8.40M
FCF Per Share	-$0.42

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -781.35% and -761.92%.

Gross Margin	100.00%
Operating Margin	-781.35%
Pretax Margin	-761.92%
Profit Margin	-761.92%
EBITDA Margin	-756.73%
EBIT Margin	-761.92%
FCF Margin	-59.92%

Dividends & Yields

Immunome does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-63.64%
Shareholder Yield	-63.64%
Earnings Yield	-17.57%
FCF Yield	-1.38%

Analyst Forecast

The average price target for Immunome is $34.00, which is 131.45% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$34.00
Price Target Difference	131.45%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Immunome has an Altman Z-Score of 9.34 and a Piotroski F-Score of 2.

Altman Z-Score	9.34
Piotroski F-Score	2